Tofacitinib Might Be Effective for Severe, Recalcitrant Atopic Dermatitis

This pilot study shows promise.

Atopic dermatitis (AD) can be severe and require systemic therapy for its management. Systemic corticosteroids are effective but are frequently associated with adverse reactions and are noted for tachyphylaxis (diminished response) with continued usage. Various immunosuppressive agents have been used successfully, including azathioprine, mycophenolate, cyclosporine, and methotrexate, in some patients with AD. The pathogenesis of AD is becoming clearer and is generally believed to involve Th2 immune cells. Some evidence also suggests that Janus kinase (JAK) inhibitors might play a role in down-regulating the relevant pathway.

These investigators report the results of an open-label, prospective study of six patients with recalcitrant AD. Other…

Reviewing Author

Jeffrey P. Callen, MD

Disclosures

Consultant / Advisory board XOMA; Eli Lilly; Celgene

Equity Various trust accounts

Editorial boards JAMA Dermatology; UpToDate

Leadership positions in professional societies Association of Professors of Dermatology (President-Elect)